Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of sulfonamide and phenyl, applied in the field of heteroarylsulfonamide derivatives
Inactive Publication Date: 2013-07-17
PIERRE FABRE MEDICAMENT SAS
View PDF5 Cites 7 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, the risk of embolism is only partially conditional on the presence of FA alone, since atrial congestion is also associated with increased intraluminal pressure (systolic or diastolic LV dysfunction, valvular heart disease or valve replacement)
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0271] Example 1 : N-(2-(4-(6-fluorobenzo[d]oxazol-2-yl)piperazine-1-carbonyl)phenyl)-5-(trifluoromethyl)pyridine-2-sulfonamide (1)
[0272]
[0273] Compound 1 was prepared using Synthetic Method 1: In the presence of 1H-benzo[d][1,3]oxazine-2,4-dione (1.83 g, 11.3 mmol) and DMAP (138 mg, 1.13 mmol), the Intermediate 3a (2.5 g, 11.30 mmol) was taken up in 25 mL THF and 5 mL DMF, and the mixture was stirred at ambient temperature overnight. After concentration to dryness, the residue was taken up in water and extracted with AcOEt. After drying the organic phase and concentrating to dryness, the residue obtained was purified by flash chromatography on silica gel (CH 2 Cl 2 -MeOH, gradient 100-0 to 95-5 over 40 minutes). 0.47 g of solid were obtained (yield: 32%). The obtained solid was then placed in 3 mL of dichloromethane in the presence of 0.119 g (0.48 mmol) of intermediate 4a and 39 μL of pyridine. The mixture was then stirred overnight at ambient temperature, t...
Embodiment 2
[0277] Example 2 : N-(2-(4-(6-fluorobenzo[d]thiazol-2-yl)piperazine-1-carbonyl)phenyl)-pyridine-2-sulfonamide (2)
[0278]
[0279] Compound 2 was prepared using Synthetic Method 1 using Intermediate 3e (yield: 87%) for the first step and Intermediate 4b (yield: 30%) for the second step.
[0283] Example 3 : N-(2-(4-(6-bromobenzo[d]thiazol-2-yl)piperazine-1-carbonyl)phenyl)-pyridine-2-sulfonamide (3)
[0284]
[0285] Compound 3 was prepared using Synthetic Method 1 using intermediate 3f for the first step (quantitative yield) and intermediate 4b for the second step (yield: 80%).
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The present invention concerns derivatives of heteroarylsulfonamides, notably as blockers of Kv potassium channels, and more particularly of channels Kv1.5, Kv4.3 or Kv11.1, their application in clinical therapy and their preparation methods. These compounds correspond to the following general formula (I): where R1 represents one or more substituents of the phenyl core X such as: hydrogen, halogen, trifluoromethyl, trifluoromethoxy, linear or branched C1-C4 alkyl, or linear or branched C1-C4 alkoxy, A represents oxygen or sulphur, B represents nitrogen when n=1 or 2 and D represents -C(=O)-, or B represents CH when n=0 and D represents -CH2O- or when n=1 and D represents -O-, R2 represents a hydrogen, a methyl, a fluorine or chlorine atom or a methoxy, HetAr represents a pyridyl or quinolyl group, possibly substituted by a group such as a linear or branched C1-C4 alkyl, a linear or branched C1-C4 alkoxy, a halogen, or a trifluoromethyl, and to their pharmaceutically acceptable salts.
Description
technical field [0001] The present invention relates to heteroaryl sulfonamide derivatives, their preparation method and their application in human therapy, which are used as blockers of Kv potassium channels, especially channels Kv1.5, Kv4.3 and Kv11.1. Background technique [0002] Potassium channels represent the largest family of ion channels in the human genome, with approximately 80 genes (Tamargo et al., Cardiovasc. Res. 2004, 62:9-33). These potassium channels can be subdivided into 3 subfamilies: by potential or voltage (K v channel) and calcium (K Ca channel) activated channel, inwardly rectifying channel (K ir ) and two-pore potassium channels (K 2p ). The voltage-activated channel subfamily is the most representative one in the human body, in excitable cells (cardiomyocytes, neurons, striated muscle or smooth muscle cells) and non-excitable cells such as pancreatic cells, prostate cells, parathyroid cells, etc. Has a nearly ubiquitous distribution (for revie...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more